IMPROVED VECTORS FOR THERAPEUTIC PROTEIN PRODUCTION

随着我们对分泌的天然肽数量不断增加的功能的阐明，潜在的生物治疗蛋白的多样性正在不断增加。此外，单链抗体作为多种疾病状态的治疗药物正显示出前景。大量有潜力的蛋白质疗法要求改进生产蛋白质的方法，以满足动物疗效试验和临床应用的需要。我们最近设计了一种基于改良牛乳头瘤病毒（BPV）复制子的episomal载体，它可以在多种细胞类型（包括目前用于大规模蛋白质生产的细胞类型）中作为稳定的episomal载体维持。在这个应用中，我们建议将该载体用于制造治疗性血浆蛋白。建议的商业应用：不可用

The diversity of potential biotherapeutic proteins is continuously rising as we elucidate the function of an ever-increasing number of secreted natural peptides. In addition, single-chain antibodies are showing promise as therapeutic agents for a variety of disease states. This profusion of potentially promising protein therapies demands improvements in the methods used for producing proteins on the scale necessary to meet demands for efficacy trials in animals and for use in the clinic. We have recently devised an episomal vector based upon a modified bovine papilloma virus (BPV) replicon that can be maintained as a stable episome in a wide variety of cell types, including those currently used for large-scale protein production. In this application, we propose the adaptation of this vector for use in the manufacture of therapeutic plasma proteins. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE